<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923610</url>
  </required_header>
  <id_info>
    <org_study_id>RisVac02 boost</org_study_id>
    <nct_id>NCT01923610</nct_id>
  </id_info>
  <brief_title>Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B</brief_title>
  <official_title>Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      24 healthy male and female volunteers who are at low risk of HIV infection and entered into&#xD;
      the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of MVA-B&#xD;
      at weeks 0, 4 and 16 will receive a boosting dose 4 years thereafter.&#xD;
&#xD;
      Participants will attend one of two clinical centres on at least 5 occasions over 16 weeks.&#xD;
      These visits will comprise:&#xD;
&#xD;
        -  Screening&#xD;
&#xD;
        -  Trial entry and boosting immunisation&#xD;
&#xD;
        -  Early follow-up after immunisation&#xD;
&#xD;
        -  Follow-up x 2 including the final visit Participants will have blood and urine&#xD;
           collected, and receive 1 immunisation. They will be counselled prior to and following a&#xD;
           HIV test, and given health education on prevention of sexually transmitted infections&#xD;
           including HIV. T&#xD;
&#xD;
      The two centres which participate are:&#xD;
&#xD;
        -  Hospital Clinic, Barcelona and&#xD;
&#xD;
        -  Hospital Gregorio Marañón, Madrid The primary objective is to explore the safety and&#xD;
           immunogenicity of MVA-B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local adverse event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Grade 3 or above local adverse event (pain, cutaneous reactions including induration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 or above systemic adverse event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3 or above other clinical or laboratory adverse event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event attributable to vaccine leading to discontinuation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Any event attributable to vaccine leading to discontinuation of the immunisation regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary immunogenicity parameters</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary immunogenicity parameters will be quantitative or present/absent, and are cellular responses - CD8/CD4+ T cell responses (ELISPOT) at week 2, 4 and 12 following the immunisations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All grade 1 and 2 adverse events</measure>
    <time_frame>28 days of vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody responses</measure>
    <time_frame>12 weeks</time_frame>
    <description>binding titration to the construct MVAB&#xD;
binding titration to and neutralisation of vaccinia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cellular responses</measure>
    <time_frame>12 weeks</time_frame>
    <description>CD8/CD4+ T cell responses (ELISPOT) at week 0&#xD;
intracellular cytokine analysis at week 0, 2, 4 and 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Main</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVA HIV-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)&#xD;
-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16</description>
    <arm_group_label>Main</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female&#xD;
&#xD;
          -  age between 18 and 55 years on the day of screening&#xD;
&#xD;
          -  available for follow-up for the duration of the study (52 weeks from screening)&#xD;
&#xD;
          -  able to give written informed consent&#xD;
&#xD;
          -  at low risk of HIV and willing to remain so for the duration of the study low risk of&#xD;
             HIV infection defined as: no history of injecting drug use in the previous ten years&#xD;
             no gonorrhoea or syphilis in the last six months no high risk partner (e.g. injecting&#xD;
             drug use, HIV positive partner) either currently or within the past six months no&#xD;
             unprotected anal intercourse in the last six months no unprotected vaginal intercourse&#xD;
             outside a relationship with a regular known/presumed HIV negative partner in the last&#xD;
             six months&#xD;
&#xD;
          -  willing to undergo a HIV test&#xD;
&#xD;
          -  willing to undergo a genital infection screen&#xD;
&#xD;
          -  if heterosexually active female, using an effective method of contraception with&#xD;
             partner (combined oral contraceptive pill; injectable contraceptive; IUCD; consistent&#xD;
             record with condoms if using these; physiological or anatomical sterility in self or&#xD;
             partner) from 14 days prior to the first vaccination until 4 months after the last,&#xD;
             and willing to undergo urine pregnancy tests prior to each vaccination&#xD;
&#xD;
          -  if heterosexually active male, using an effective method of contraception with their&#xD;
             partner from the first day of vaccination until 4 months after the last vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  positive for hepatitis B surface antigen, hepatitis C antibody, antibody responses to&#xD;
             vaccinia or serology indicating active syphilis requiring treatment&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  clinically relevant abnormality on history or examination including history of&#xD;
             grand-mal epilepsy, severe eczema, immunodeficiency or use of immunosuppressives in&#xD;
             preceding 3 months&#xD;
&#xD;
          -  receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of&#xD;
             enrolment&#xD;
&#xD;
          -  receipt of blood products or immunoglobin within 4 months of screening&#xD;
&#xD;
          -  participation in another trial of a medicinal product, completed less than 30 days&#xD;
             prior to enrolment&#xD;
&#xD;
          -  history of severe local or general reaction to vaccination defined as local:&#xD;
             extensive, indurated redness and swelling involving most of the front-lateral thigh or&#xD;
             the major circumference of the arm, not resolving within 72 hours general: fever &gt;=&#xD;
             39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal&#xD;
&#xD;
          -  HIV 1/2 positive or indeterminate on screening&#xD;
&#xD;
          -  positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating&#xD;
             active syphilis requiring treatment&#xD;
&#xD;
          -  grade 1 routine laboratory parameters&#xD;
&#xD;
          -  unlikely to comply with protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Low risk HIV infection</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

